BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

Fresh off its $200 million IPO last month, Generation Bio Co. (NASDAQ:GBIO) has added Matthew Norkunas as CFO. Norkunas, who succeeds interim CFO Stephen DiPalma, was CFO of SomaLogic Inc. IQVia Holdings Inc. (NYSE:IQV) has...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy  FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 16, 2020
Product Development

AC Immune’s biggest stock move this year likely to come from tau mAb

The 19% stock bump of neurodegeneration play AC Immune S.A. (NASDAQ:ACIU) on Thursday may have reflected excitement about the target of the company’s anti-tau vaccine for Alzheimer’s disease more than any new information about the...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

After the sudden, COVID-driven market declines that closed out 1Q20, biotech stocks rebounded in the second quarter with a force that has put shares up year to date. Many of the biggest moves came from...
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout  Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer...
BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

Luminary, Case Western partner on CAR T against BLyS  Minneapolis-based Luminary Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS target for use in CAR T constructs; financial...
BioCentury | Jul 2, 2020
Finance

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move...
Items per page:
1 - 10 of 4883
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

Fresh off its $200 million IPO last month, Generation Bio Co. (NASDAQ:GBIO) has added Matthew Norkunas as CFO. Norkunas, who succeeds interim CFO Stephen DiPalma, was CFO of SomaLogic Inc. IQVia Holdings Inc. (NYSE:IQV) has...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy  FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 16, 2020
Product Development

AC Immune’s biggest stock move this year likely to come from tau mAb

The 19% stock bump of neurodegeneration play AC Immune S.A. (NASDAQ:ACIU) on Thursday may have reflected excitement about the target of the company’s anti-tau vaccine for Alzheimer’s disease more than any new information about the...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

After the sudden, COVID-driven market declines that closed out 1Q20, biotech stocks rebounded in the second quarter with a force that has put shares up year to date. Many of the biggest moves came from...
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout  Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer...
BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

Luminary, Case Western partner on CAR T against BLyS  Minneapolis-based Luminary Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS target for use in CAR T constructs; financial...
BioCentury | Jul 2, 2020
Finance

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move...
Items per page:
1 - 10 of 4883